Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5513 Alone or With QL1706 in Previously Treated Advanced or Metastatic TNBC
NCT07509515Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of QLC5513 in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
QLC5513
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07509515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509515.